Quadrivas Therapy® to Reduce Lipedema Subcutaneous Adipose Tissue (QUADRIVAS) (QUADRIVAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02907411
Recruitment Status : Completed
First Posted : September 20, 2016
Last Update Posted : September 15, 2017
Hanger Clinic
Quadrivas Therapy Clinic & Academy Amsterdam
Information provided by (Responsible Party):
KHerbst, University of Arizona

Brief Summary:
Quad Rivas Therapy has been developed by Alyna Eekma from the Netherlands for over thirteen years; anecdotally she has been able to significantly reduce lipedema SAT in women with Stage 1 and 2 lipedema, and can reduce lipedema SAT by 80% in women with Stage 3 lipedema. The study will last for one month, for a total of 12 treatments per subject, seven subjects total, to see if there is a change in percent body fat percentage over the course of these treatments.

Condition or disease Intervention/treatment
Lipedema Other: Quadrivas Therapy

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Quadrivas Therapy® to Reduce Lipedema Subcutaneous Adipose Tissue (QUADRIVAS)
Study Start Date : September 1, 2016
Primary Completion Date : March 18, 2017
Study Completion Date : March 18, 2017

Arm Intervention/treatment
Experimental: Quadrivas Therapy
Hands on therapy to improve all aspects of fat tissue including the vessels within. Each of 7 subjects receive 12 treatments in one month time.
Other: Quadrivas Therapy
Quadrivas therapy will be applied to subjects. Quadrivas therapy is a intensive massage therapy for different tissues. Subjects will receive 12 treatments. The first lasting 2.5 hours and the remaining 11 lasting 1.5 hours.

Primary Outcome Measures :
  1. Full Body Fat Percentage [ Time Frame: Baseline and 4 weeks ]
    Change in full body fat percentage after 4 weeks of treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Ambulatory females of any race able to understand the consent process.
  2. 19-70 years of age.
  3. Diagnosis of lipedema Stage 1 or Stage 2 although early Stage 3 will be considered.
  4. Weight stable for past three months per personal report of the subject.
  5. Must be able to attend all 12 treatments and pre and post procedures

Exclusion Criteria:

  1. Use of medications that might cause weight gain and prevent fat loss (e.g., second generation anti-psychotics, corticosteroids).
  2. Current use of weight loss medications.
  3. Tobacco or marijuana use which may alter inflammation in the body.
  4. Pregnancy due to the risks associated with deep tissue treatment.
  5. Two or more alcoholic beverages per day, chronically.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02907411

United States, Arizona
The Herbst Clinic
Tucson, Arizona, United States, 85711
Clinical and Translational Sciences Research Center (CATS) at the University of Arizona
Tucson, Arizona, United States, 85724-5099
Sponsors and Collaborators
University of Arizona
Hanger Clinic
Quadrivas Therapy Clinic & Academy Amsterdam
Principal Investigator: Karen L Herbst, MD, PhD University of Arizona

Additional Information:
Responsible Party: KHerbst, Associate Professor, TREAT Program Director, University of Arizona Identifier: NCT02907411     History of Changes
Other Study ID Numbers: 1607696709
First Posted: September 20, 2016    Key Record Dates
Last Update Posted: September 15, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The data will be shared with investigators who submit a request

Keywords provided by KHerbst, University of Arizona:

Additional relevant MeSH terms:
Connective Tissue Diseases